商湯(00020.HK)夥富士膠片商業創新推SensePrint商湯智印解決方案
商湯科技(00020.HK)公布,近日與富士膠片商業創新(中國)達成合作,共同推出SensePrint商湯智印解決方案,集打印、複印、掃描和傳真功能於一身的富士膠片商業創新智能型數碼多功能機將全面搭載該解決方案,通過一人認證一人使用的方式提升用戶私密性。
此外SensePrint商湯智印解決方案結合文印管理解決方案,可實現點對面拉取式打印,即使用者可在公司任意同網數碼多功能機刷臉打印,大大提高便利性。
商湯表示,未來將繼續秉承負責任的AI理念,與富士膠片商業創新協同創新,挖掘人工智能技術在智能文印行業的更多應用場景。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.